학술논문
Durvalumab impacts progression-free survival while high-dose radiation >66 Gy improves local control without excess toxicity in unresectable NSCLC stage III: Real-world data from the Austrian radio-oncological lung cancer study association registry (ALLSTAR)
Document Type
Article
Author
Zehentmayr, Franz; Feurstein, Petra; Ruznic, Elvis; Langer, Brigitte; Grambozov, Brane; Klebermass, Marisa; Hüpfel, Herbert; Feichtinger, Johann; Minasch, Danijela; Heilmann, Martin; Breitfelder, Barbara; Steffal, Claudia; Gastinger-Grass, Gisela; Kirchhammer, Karoline; Kazil, Margit; Stranzl, Heidi; Dieckmann, Karin
Source
In Radiotherapy and Oncology July 2024 196
Subject
Language
ISSN
0167-8140